Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and composition for treating prostate cancer

A technology for prostate cancer and composition, applied in the directions of drug combination, carbohydrate active ingredients, sugar derivatives, etc., can solve problems such as impotence, incontinence, death, etc.

Inactive Publication Date: 2002-12-11
IMMUNOLYTICS
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But this treatment can lead to death, incontinence, impotence, damage to the rectum, or pulmonary embolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0084] Preparation and testing of the indicated compositions

[0085] The present invention discloses as a preferred embodiment an aqueous solution of a composition for topical application containing safe and therapeutically effective concentrations of the hydrolase collagenase and hyaluronidase descaling agent Triton(R) X-100 and the antibiotic gentamicin. Preferably, the disclosed compositions are prepared as a relatively concentrated aqueous solution of the hydrolase in a relatively small volume.

[0086] Preferably, the disclosed compositions are presented in unit formulations suitable for intraprostatic injection. Injectable dosage forms, which may be solutions or suspensions of the compound in a physiologically acceptable liquid diluent, such as pyrogen-free saline, are suitable for use in patients. For example, vials containing the lyophilized composition can be prepared so that the sterile components of the composition can be reconstituted to obtain a pharmaceutically...

Embodiment 1

[0136] Example 1: First Case of Study of Men with Localized Prostate Cancer

[0137] A 70-year-old man was diagnosed with non-spread prostate cancer (ie, no spread as detected by radionuclide scan and CAT scan). The estimated size of the tumor within the prostate was 7 grams. According to the sonogram, the location of the tumor is the right lobe. The blood PSA level was 40 ng / ml.

[0138] A composition for injection was prepared as described above (preparation and testing of compositions), comprising 12,500 U / ml collagenase, 7,500 U / ml hyaluronidase, 1% (v / v) Triton® X-100, 150 μg / ml Gentamicin and 40 mmol CaCl 2 0.05M citrate buffered saline (Ph6.7). The final composition was injected into a syringe (5cc) for injection.

[0139] The patient is given local anesthesia before cystoscopy. A cystoscope is placed in the urethra and a needle is inserted into the lesion (tumor) and monitored with ultrasound imaging. Once the needle is secured, 5 cc of the composition for injec...

Embodiment 2

[0141] Example 2: A second case of a man with localized prostate cancer

[0142] A 65-year-old man was diagnosed with localized prostate cancer (ie, no spread as detected by radionuclide scan and CAT scan). The estimated size of the tumor within the prostate is 15 grams. The location of the tumor is the right lobe and it is a solid tumor.

[0143] A composition for injection was prepared as described above (preparation and testing of compositions), including 2,400 U / ml collagenase, 1,600 U / ml hyaluronidase, 1% (v / v) Triton® X-100, 150 μg / ml Gentamicin and 120mmol CaCl 2 0.05M citrate buffered saline (Ph6.7). The total volume of the injection is 30cc.

[0144] The composition is injected into the tumor under the supervision of a cystoscope. First, a 5cc dose is injected slowly. Then, pour the remaining 25cc slowly over about 25-20 minutes. After completion of the injection, monitor for vital signs indicative of intoxication, anaphylaxis, or other adverse reactions.

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

A method of treating prostate cancer in a living mammal comprising the topical administration of a composition containing a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes topical administration of a protein containing a therapeutically effective concentration of collagenase and at least one glycosidase, protease, nuclease, lipase, esterase, plasminogen activator, streptokinase and their mixtures. Preferably a glycosidase enzyme such as hyaluronidase is administered. Compositions useful in methods of treating prostate cancer also include or are administered together with calcium ions, nonionic surfactants such as Triton RX-100, and antibiotics such as gentamicin. Other methods of treating prostate cancer in living mammals include activation of prostate-specific-antigen (PSA) in vivo, such as by local administration of calcium ions.

Description

field of invention [0001] The present invention relates to a method for treating prostate cancer by administering collagenase alone or in combination with glycosidase, protease, nuclease, lipase, esterase, streptokinase or mixtures thereof. Typical embodiments include administering a composition comprising a mixture of collagenase, hyaluronidase, nonionic surfactant, antibiotic and calcium ions. Background of the invention [0002] Today it is believed that approximately 10,000,000 American men suffer from prostate cancer. Although less than 3 percent of men with the disease die from it, prostate cancer remains the second leading cause of cancer death in men. This cancer is usually confined to the prostate, but in some cases the cancer has spread to the bones, kidney, or brain when it is diagnosed. [0003] Annual screening for the disease increases the likelihood of early detection, especially before the disease spreads. These tests include a digital rectal examination a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H15/234A61K31/7036A61K33/06A61K38/16A61K38/46A61K38/48A61K38/54A61K45/00A61K45/06A61P13/08A61P35/00
CPCA61K38/164A61K38/4886A61K45/06A61K33/06A61P13/08A61P35/00A61K38/47A61K31/70A61K2300/00
Inventor M·高克森
Owner IMMUNOLYTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com